Compliance to fingolimod and other disease modifying treatments in multiple sclerosis patients, a retrospective cohort study

Compliance to fingolimod and other disease modifying treatments in multiple sclerosis patients, a retrospective cohort study

Bibliographic Details
Main Authors:	Agashivala, Neetu, Wu, Ning, Abouzaid, Safiya, Wu, You, Kim, Edward, Boulanger, Luke, Brandes, David W
Format:	Online
Language:	English
Published:	BioMed Central 2013
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3851325/

Similar Items

A cross-sectional survey of patient satisfaction and subjective experiences of treatment with fingolimod
by: Hanson, Kristin A, et al.
Published: (2013)

Treatment selection and experience in multiple sclerosis: survey of neurologists
by: Hanson, Kristin A, et al.
Published: (2014)

Relapse Rates in Patients with Multiple Sclerosis Switching from Interferon to Fingolimod or Glatiramer Acetate: A US Claims Database Study
by: Bergvall, Niklas, et al.
Published: (2014)

Critical appraisal of the role of fingolimod in the treatment of multiple sclerosis
by: Warnke, Clemens, et al.
Published: (2011)

Myeloid cells as target of fingolimod action in multiple sclerosis
by: Di Dario, Marco, et al.
Published: (2015)

A concise synthesis of Fingolimod: an orally available drug for treating multiple sclerosis
by: Yan, Ning, et al.
Published: (2015)

Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial
by: Calkwood, Jonathan, et al.
Published: (2014)

Efficacy of fingolimod is superior to injectable disease modifying therapies in second-line therapy of relapsing remitting multiple sclerosis
by: Braune, Stefan, et al.
Published: (2015)

Fingolimod (Gileyna, FTY720): Innovative treatment for multiple sclerosis
by: Pinki,, et al.
Published: (2011)

Evidence-based assessment of potential use of fingolimod in treatment of relapsing multiple sclerosis
by: Portaccio, Emilio
Published: (2011)

Fingolimod (FTY720): First approved oral therapy for multiple sclerosis
by: Sharma, Sushil, et al.
Published: (2011)

Advances in the treatment of relapsing—remitting multiple sclerosis — critical appraisal of fingolimod
by: Gasperini, Claudio, et al.
Published: (2013)

Early Bilateral Cystoid Macular Oedema Secondary to Fingolimod in Multiple Sclerosis
by: Liu, Lei, et al.
Published: (2012)

Safety and Efficacy of Fingolimod in Treatment-Naïve Multiple Sclerosis Patients
by: Marriott, James J.
Published: (2011)

The First Dose of Fingolimod Affects Circulating Extracellular Vesicles in Multiple Sclerosis Patients
by: Matías Sáenz-Cuesta, et al.
Published: (2018-08-01)

Long-term effects of fingolimod in multiple sclerosis: The randomized FREEDOMS extension trial
by: Kappos, Ludwig, et al.
Published: (2015)

Peripheral Blood T Cell Dynamics Predict Relapse in Multiple Sclerosis Patients on Fingolimod
by: Song, Zi-Ye, et al.
Published: (2015)

Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis
by: Kuhle, Jens, et al.
Published: (2015)

The real-world patient experience of fingolimod and dimethyl fumarate for multiple sclerosis
by: Wicks, Paul, et al.
Published: (2016)

Clinical efficacy, safety, and tolerability of fingolimod for the treatment of relapsing-remitting multiple sclerosis
by: Gajofatto, Alberto, et al.
Published: (2015)

Acute Lymphoblastic Leukemia in a Man Treated With Fingolimod for Relapsing Multiple Sclerosis
by: Cohan, Stanley, et al.
Published: (2015)

The Direct Effects of Fingolimod in the Central Nervous System: Implications for Relapsing Multiple Sclerosis
by: Hunter, Samuel F., et al.
Published: (2015)

Retinal hemorrhages following fingolimod treatment for multiple sclerosis; a case report
by: Ueda, Naoko, et al.
Published: (2015)

Patient experience and practice trends in multiple sclerosis – clinical utility of fingolimod
by: Lee, Jong-Mi, et al.
Published: (2015)

Effect of Fingolimod on Platelet Count Among Multiple Sclerosis Patients
by: Farrokhi, Mehrdad, et al.
Published: (2015)

Fingolimod in active multiple sclerosis: an impressive decrease in Gd-enhancing lesions
by: Muris, Anne-Hilde, et al.
Published: (2014)

Fingolimod Increases CD39-Expressing Regulatory T Cells in Multiple Sclerosis Patients
by: Muls, Nathalie, et al.
Published: (2014)

Clinical implications for substandard, nonproprietary medicines in multiple sclerosis: focus on fingolimod
by: Correale, Jorge, et al.
Published: (2016)

Antidepressant activity of fingolimod in mice
by: di Nuzzo, Luigi, et al.
Published: (2015)

Patient perspectives on switching disease-modifying therapies in the NARCOMS registry
by: Salter, Amber R, et al.
Published: (2014)

Analysis of the relationship between psoriasis symptom severity and quality of life, work productivity, and activity impairment among patients with moderate-to-severe psoriasis using structural equation modeling
by: Lewis-Beck, Colin, et al.
Published: (2013)

Economic Burden Associated with Extrapyramidal Symptoms in a Medicaid Population with Schizophrenia
by: Abouzaid, Safiya, et al.
Published: (2012)

Fingolimod: The first oral drug approved by food and drug administration; A breakthrough in treatment of multiple sclerosis
by: Singh, Manish, et al.
Published: (2011)

Development of oral agent in the treatment of multiple sclerosis: how the first available oral therapy, fingolimod will change therapeutic paradigm approach
by: Gasperini, Claudio, et al.
Published: (2012)

Fingolimod in the treatment algorithm of relapsing remitting multiple sclerosis: a statement of the Central and East European (CEE) MS Expert Group
by: Fazekas, Franz
Published: (2012)

Cost analysis of glatiramer acetate vs. fingolimod for the treatment of patients with relapsing-remitting multiple sclerosis in Spain
by: Sanchez-de la Rosa, Rainel, et al.
Published: (2013)

How Does Fingolimod (Gilenya®) Fit in the Treatment Algorithm for Highly Active Relapsing-Remitting Multiple Sclerosis?
by: Fazekas, Franz, et al.
Published: (2013)

Lymphocytes subset composition and modulation of sphingosie-1-phosphate mediated migration in multiple sclerosis patients treated with fingolimod or interferon-β
by: Sic, Heiko, et al.
Published: (2012)

Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial
by: Laroni, Alice, et al.
Published: (2014)

Assessing the potential impact of non-proprietary drug copies on quality of medicine and treatment in patients with relapsing multiple sclerosis: the experience with fingolimod
by: Correale, Jorge, et al.
Published: (2014)